報價延遲最少15分鐘:2025/11/16 04:39 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.03 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-13.13/-0.61
|
|
企業價值
4.37M
|
| 資產負債 |
|
每股賬面淨值
-2.06
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/11/16 04:39 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders. |
